Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2009 by The Huesped Foundation.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Pfizer
Information provided by:
The Huesped Foundation
ClinicalTrials.gov Identifier:
NCT01013987
First received: November 13, 2009
Last updated: February 9, 2010
Last verified: November 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Study Completion Date: No date given
  Primary Completion Date: No date given